From 17-21 September, the biennial EDCTP Forum will bring together researchers from around the...
PACA aims to provide a platform for scientists, technologists and industrial partners in...
The 5th South African TB Conference entitled “Step-Up! Let’s Embrace All to End TB!” will take...
The EDCTP has recently published its Annual Report 2016, highlighting the programme’s work in the...
The start of PredictTB and the Kick-Off Meetings in China and Cape Town have been reported on in...
World TB day on 24 March hopes to highlight the global burden of Tuberculosis (TB) and the...
The PredictTB project, which will receive over 20 million EUR funding over the next five years from...
An article on PredictTB was published today in “The Conversation”, an independent source of news...
PredictTB is a five-year project financed by a variety of international funders and implemented by American, African, Asian and European partners, that aims to shorten the treatment times of tuberculosis (TB) in drug-sensitive patients through individualized therapy.
Coordinated by Prof. Clifton Barry from the US National Institutes of Health and Prof. Gerhard Walzl from Stellenbosch University in South Africa, the consortium will perform an ambitious phase 2B clinical trial in South Africa and China and develop a set of criteria to reduce TB treatment times using data from scans, assays and cultures to evaluate inflammation and lung pathology, to test for the sustained presence of bacteria, and to determine which patients are eligible for treatment that is much shorter than the current standard of care.Read more
PredictTB aims to enroll and follow-up 620 patients with drug sensitive pulmonary TB in a clinical trial to validate candidate biomarkers as well as identify and evaluate new, improved criteria that can identify patients who can be cured with shorter treatment.
Sample collection & storage
The consortium will collect and store biological samples (including serum, whole blood RNA, sputum, saliva, and urine) from patients in Africa and Asia for future biomarker research.
Project partners in the Netherlands will develop a point-of-care lateral flow device that helps doctors decide which patients are eligible for shortened treatment.